Halozyme Therapeutics, Inc.
HALO
$63.65
-$1.48-2.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -180.81% | 6.09% | 39.85% | -13.81% | 0.00% |
| Total Depreciation and Amortization | 30.66% | -0.40% | 0.26% | 0.17% | 0.27% |
| Total Amortization of Deferred Charges | 4.95% | 0.32% | 0.33% | 0.11% | 0.16% |
| Total Other Non-Cash Items | 767.12% | 833.92% | -33.70% | 203.01% | -161.10% |
| Change in Net Operating Assets | 83.82% | 36.67% | -1,331.52% | -70.55% | 147.03% |
| Cash from Operations | 22.64% | 79.11% | -35.35% | -13.59% | 54.68% |
| Capital Expenditure | 52.90% | -93.86% | -64.53% | 68.87% | -101.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -107.03% | 136.99% | 196.51% | -375.03% | 119.60% |
| Cash from Investing | -467.93% | 137.78% | 193.77% | -406.72% | 117.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -74.84% | 1,271.13% | -- | -- | -80.69% |
| Repurchase of Common Stock | 100.00% | 87.05% | -8,938.48% | 98.67% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,169.17% | 92.51% | -8,902.29% | 98.65% | -1,427.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -179.16% | 412.58% | -289.27% | 257.22% | -14.67% |